84594-95-6

Basic information

• Product Name: Iguratimod Impurity 5
• Synonyms: Iguratimod Impurity 5;4-methoxy-2-nitro-1-phenoxybenzene
• CAS NO: 84594-95-6
• Molecular Formula: C₁₃H₁₁NO₄
• Molecular Weight: 245.23074
• Mol File: 84594-95-6.mol
• Article Data: 4

Chemical Properties

• Melting Point: 35 °C(Solv: methanol (67-56-1))
• Boiling Point: 162-165 °C(Press: 0.5 Torr)
• Appearance: /
• Density: 1.252±0.06 g/cm3(Predicted)
• CAS DataBase Reference: Iguratimod Impurity 5(CAS DataBase Reference)
• NIST Chemistry Reference: Iguratimod Impurity 5(84594-95-6)
• EPA Substance Registry System: Iguratimod Impurity 5(84594-95-6)

Safety Data

• Hazardous Substances Data: 84594-95-6(Hazardous Substances Data)

Usage

General Description

Iguratimod Impurity 5 is a chemical compound that serves as an impurity in the production of the drug iguratimod. It is used in the pharmaceutical industry for research and development purposes, as well as in the quality control of iguratimod production. Iguratimod Impurity 5 is a key component in ensuring the purity and efficacy of iguratimod and plays a significant role in the overall safety and effectiveness of the drug. Its chemical structure and properties are carefully studied and monitored to comply with regulatory standards and ensure the consistency and quality of iguratimod.

Upstream product

• 5344-78-5 4-bromo-3-nitroanizole 
• 100-67-4 potassium phenolate 
• 12775-96-1 copper 
• 108-95-2 phenol 
• 10298-80-3 2-chloro-5-methoxynitrobenzene 

Downstream Products

• 102077-92-9 4',5-Dimethoxy-2-phenoxy-diphenyl-ether 
• 105904-57-2 2-Brom-4-methoxy-diphenylaether 
• 1655-69-2 1-methoxy-4-phenoxy-benzene 
• 76838-31-8 1-Benzoyl-3-(5-hydroxy-2-phenoxy-phenyl)-thiourea 
• 76841-06-0 3-(Imidazolidin-2-ylideneamino)-4-phenoxy-phenol 
• 76839-11-7 (5-Hydroxy-2-phenoxy-phenyl)-thiourea 
• 123664-66-4 7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one-2-carboxylic acid azide 
• 123663-74-1 2-ethoxycarbonyl-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one 
• 123664-54-0 N-(4-acetyl-5-benzyloxy-2-phenoxy-phenyl)-methanesulfonamide 
• 123663-75-2 7-[(methylsulfonyl)amino]-4-oxo-6-phenoxy-4H-2-chromonecarboxylic acid 
• 123664-65-3 7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one-2-carboxylic acid chloride 
• 123663-72-9 7-[(methylsulfonyl)amino]-4-oxo-6-phenoxy-4H-1-benzopyran-3-carboxamide 
• 123663-69-4 3-carboxy-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one 
• 149457-03-4 α-formamido-2'-hydroxy-4'-methanesulfonamido-5'-phenoxyacetophenone 

Relevant articles and documents

COMPOUNDS COMPRISING N-METHYL-2-PYRIDONE, AND PHARMACEUTICALLY ACCEPTABLE SALTS

The present invention concerns compounds comprising N-methyl-2-pyridone, and pharmaceutically-acceptable salts and compositions of such compounds. Such compounds are useful in anti-inflammatory and anti-cancer therapies. Therefore, the present invention also concerns such compounds for use as medicaments, particularly for the treatment of inflammatory diseases and oncology.

Synthesis and antiinflammatory activity of 7-methanesulfonylamino-6- phenoxychromones. Antiarthritic effect of the 3-formylamino compound (T-614) in chronic inflammatory disease models

A group of derivatives of 7-methanesulfonylamino-6-phenoxychromone (1) at the pyrone and phenoxy rings was synthesized starting with 4-chloro-3- nitroanisole and evaluated against acute and chronic inflammations in oral administration in animals. Significant potency in the rat models of carrageenin-induced edema (CPE) and adjuvant-induced arthritis (AA) was realized with 2'-fluoro and 2',4'-difluoro derivatives (9a and 9d), and 3- formylamino derivative (19a) and its 2'-fluoro and 2',4'-difluoro compounds (22a and 22d), displaying AA therapeutic effect of ED40=2.5-7.1 mg/kg/d for 7 d and AA prophylactic effect of 53-70% inhibition at the dosage of 3 mg/kg/d for 22 d. To identify a candidate for further pharmacological study, the five compounds were subjected to evaluation of their gastro-ulcerogenic liability, leading to selection of the fluorine-free compound 19a which did not cause acute ulceration at 300 mg/kg in oral administration in rats. Compound 19a (ED40=3.6 mg/kg in established AA) possessed good therapeutic efficacy against type II collagen-induced arthritis in DBA/1J mice with doses of 30 and 100 mg/kg, suggesting the development of 19a (designated T-614) as a prospective disease-modifying antirheumatic agent. In addition, a preparative-scale synthetic route to T-614 has been established.